Headline Shiseido Q1 Sales Mask Stronger Profit and Portfolio Shifts
Shiseido’s first-quarter update shows a 3% decline in net sales to ¥232 billion, but the topline pressure tells only part of the story. Operating profit actually jumped 58% to ¥13 billion, underscoring how cost control and portfolio optimisation are cushioning weaker revenue. The beauty group cited ongoing geopolitical tensions and timing shifts across several brands, as well as inventory adjustments, as key drags on performance. Within its core names, Shiseido-branded products fell 4%, while prestige label Clé de Peau slipped 2%. Yet other franchises bucked the trend, with NARS growing 7% and Elixir up 4%. The result is a complex beauty brand earnings picture: headline sales are under pressure, but selective strength in colour cosmetics and targeted skincare suggests the group is reshaping its mix rather than simply shrinking.
Geopolitics and Restructuring Weigh on the Skincare Market Environment
Shiseido’s results underline how skincare market challenges are increasingly tied to geopolitics and supply chains rather than demand alone. The company linked softer performance to tensions between Japan and China, triggered after political comments in late 2025, which contributed to a 1% decline in its China and Travel Retail segment. It also warned that conflict in the Middle East is driving raw material and logistics cost pressures, and could disrupt supply chains through production delays. Against this backdrop, Shiseido is streamlining its global production network, including closing the Hsinchu factory of Taiwan Shiseido and shifting output to domestic bases. At the same time, management is evaluating selective price increases to offset rising costs. These moves show a group trying to protect profitability and future capacity while navigating a more volatile operating environment for global beauty brands.
Drunk Elephant Recovery: From Sephora Kids Fallout to Stabilisation
Within Shiseido’s skincare portfolio, Drunk Elephant is emerging as a key test case for brand rehabilitation. The embattled label has endured multiple quarters of declining sales following its unwanted association with the 2024 “Sephora Kids” phenomenon, when tweens flocked to high-active formulas and triggered a reputational backlash. In the latest quarter, reported figures show a nuanced Drunk Elephant recovery: in one disclosure, brand sales rose 1%, while another noted a 14% decline but with a significantly narrowed year-on-year drop, signalling stabilisation. Shiseido has doubled down on turning the brand around, unveiling a refreshed campaign and new direction in January 2026 aimed at clarifying its identity and target consumer. The strategy leans on stronger engagement via brand ambassadors, partnerships and a creator community, alongside a push to regain leadership through “unrivalled” hero products that can re-anchor Drunk Elephant in the premium skincare conversation.
Selective Strength Highlights Future Direction for Shiseido’s Skincare Franchise
The mixed brand performance across Shiseido’s portfolio offers clues to where future growth may come from. While the flagship Shiseido brand and Clé de Peau declined modestly, NARS’ 7% growth and Elixir’s 4% gain highlight the resilience of certain categories and regions. Anessa’s 17% drop and a 6% decline at Dr. Dennis Gross show that not all skin-focused lines are faring equally, reinforcing that consumer preferences and competitive dynamics are highly segment-specific. In the US, Shiseido-branded products such as Vital Perfection recorded strong sales, and NARS returned to positive growth, suggesting that targeted innovation and marketing can overcome broader headwinds. For investors and industry watchers, the message is that Shiseido Q1 sales weakness sits alongside early recovery signals in skincare and colour, with Drunk Elephant’s gradual turnaround and ongoing restructuring poised to shape the group’s next phase of growth.